Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DF6215 |
Synonyms | |
Therapy Description |
DF6215 is a modified version of IL-2 that acts as an agonist for IL2R, which potentially activates cytotoxic CD8-positive T-lymphocytes and NK cells, resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DF6215 | DF-6215|DF 6215 | DF6215 is a modified version of IL-2 that acts as an agonist for IL2R, which potentially activates cytotoxic CD8-positive T-lymphocytes and NK cells, resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06108479 | Phase I | DF6215 | Study of DF6215 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |